FDA accepts BeiGene’s sNDA for follicular lymphoma therapy
13 Jul 2023
Orphan DrugLicense out/inClinical ResultPhase 2Fast Track
Preview
Source: Pharmaceutical Technology
BeiGene haematology chief medical officer Mehrdad Mobasher noted that Brukinsa is the first Bruton’s tyrosine kinase inhibitorBruton’s tyrosine kinase inhibitor to demonstrate efficacy in follicular lymphoma. Credit: BeiGene / Business Wire.
The US Food and Drug Administration (FDA) has accepted for review BeiGene’s supplemental new drug application (sNDA) for Brukinsa (zanubrutinib) plus obinutuzumab to treat relapsed or refractory (R/R) follicular lymphoma (FL).
The treatment is indicated for use in adult R/R FL patients, following a minimum of two previous lines of therapy.
Recommended Reports
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Naratuximab Emtansine in Follicular Lymphoma GlobalData
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Atezolizumab in Follicular Lymphoma GlobalData
View allCompanies IntelligenceBeiGene LtdRosewood CorpView all
A decision on the approval for the treatment is expected in the first quarter of 2024.
Brukinsa is a small molecule Bruton’s tyrosine kinase (BTK) inhibitorBruton’s tyrosine kinase (BTK) inhibitor that received fast track and orphan drug designation for R/R FL treatment.
The filing is based on findings from the Phase II ROSEWOOD clinical trial in 217 R/R non-Hodgkin FL patients, who had previously received treatment.
Safety data from the trial were in line with those from prior studies of both therapies.
Longer-term trial findings also showed that the efficacy benefit of Brukinsa plus obinutuzumab continued at a median follow-up of 20.2 months.
BeiGene haematology chief medical officer Mehrdad Mobasher stated: “Follicular lymphoma is the most common slow-growing non-Hodgkin lymphoma, but there are limited treatment options for patients whose condition has progressed after two lines of therapy.
“We are therefore pleased that Brukinsa is the first Bruton’s tyrosine kinase inhibitorBruton’s tyrosine kinase inhibitor to demonstrate efficacy in follicular lymphoma and plan to continue worldwide regulatory submissions based on the ROSEWOOD results.”
The submissions for Brukinsa in the same indication are under review in China, Canada, Switzerland, the European Union and the UK.
The latest development comes after the company entered a licence agreement for DualityBio’s antibody-drug conjugate therapy to treat certain solid tumours.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.